文献速递腹部技术与安全US

门静脉搏动指数:诊断高风险非酒精性脂肪性肝病的新型生物标志物

Portal Venous Pulsatility Index: A Novel Biomarker for Diagnosis of High-Risk Nonalcoholic Fatty Liver Disease.
PubMed 文献 · AJR Am J Roentgenol · 2020-01-15

本回顾性研究纳入123例经活检证实为非酒精性脂肪性肝病(NAFLD)的患者,采用双功能多普勒超声测量门静脉血流速度并计算门静脉搏动指数(VPI)。33例(26.8%)高风险NAFLD患者的VPI低于其他90例患者(0.19 vs 0.32,p<0.001)。VPI诊断高风险NAFLD的乐观校正AUC为0.84(95%CI 0.77-0.91),高于NAFLD纤维化评分、FIB-4和APRI,且将VPI加入任一评分系统均可显著提高诊断价值。

要点

  • VPI计算为门静脉最大与最小血流速度之差除以最大速度:(Vmax−Vmin)/Vmax。
  • 高风险NAFLD患者VPI低于非高风险患者(0.19 vs 0.32,p<0.001)。
  • VPI诊断高风险NAFLD的乐观校正AUC为0.84(95%CI 0.77-0.91)。

核心结论

  • VPI可能是一种准确的无创生物标志物,用于诊断高风险NAFLD。

研究设计与样本

  • 回顾性研究,纳入123例经活检证实为NAFLD且肝活检前后1年内接受门静脉主干双功能多普勒超声检查的患者(2014年1月至2018年2月)。

关键影像表现/征象

  • 高风险NAFLD患者VPI低于其他患者(0.19 vs 0.32;p<0.001)。

诊断标准与关键数值

  • VPI定义为(Vmax−Vmin)/Vmax,其中Vmax和Vmin分别为门静脉血流最大和最小速度。
  • VPI诊断高风险NAFLD的乐观校正AUC为0.84(95%CI 0.77-0.91)。
  • NAFLD纤维化评分诊断高风险NAFLD的乐观校正AUC为0.74(95%CI 0.63-0.83)。
  • FIB-4诊断高风险NAFLD的乐观校正AUC为0.81(95%CI 0.72-0.89)。
  • APRI诊断高风险NAFLD的乐观校正AUC为0.73(95%CI 0.61-0.82)。

临床应用与阅片要点

  • VPI、NAFLD纤维化评分、FIB-4和APRI对高风险NAFLD均具有统计学显著的诊断价值。
  • 将VPI加入四种评分系统中的任何一种,均可显著提高该评分系统对高风险NAFLD的诊断价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The purpose of this study was to assess the accuracy of portal vein pulsatility for noninvasive diagnosis of high-risk nonalcoholic fatty liver disease (NAFLD). MATERIALS AND METHODS. This retrospective study included patients with biopsy-proven diagnosis of NAFLD who underwent duplex Doppler ultrasound assessment of the main portal vein within 1 year of liver biopsy (January 2014 to February 2018). Doppler ultrasound images were reviewed. The spectral waveform was used to measure the maximum (Vmax) and minimum (Vmin) velocity of blood in the portal veins. Venous pulsatility index (VPI) defined as (Vmax - Vmin) / Vmax was calculated. ROC curve analysis was used to calculate AUC as a measure of accuracy to determine the value of this index for diagnosis of high-risk NAFLD and compared with that of the following four clinical decision aids: NAFLD fibrosis score (FS), fibrosis-4 index (FIB-4), BARD score (body mass index, aspartate aminotransferase [AST]-to-alanine aminotransferase ratio, diabetes mellitus), and AST-to-platelet ratio index (APRI). The value of adding VPI to these indexes was also investigated. RESULTS. Of 123 study subjects, 33 (26.8%) had high-risk NAFLD and were found to have a lower VPI than the other 90 subjects (0.19 vs 0.32; p < 0.001). VPI, NAFLD FS, FIB-4, and APRI had statistically significant diagnostic values for high-risk NAFLD. VPI had the highest optimism-corrected AUC (VPI, 0.84 [95% CI, 0.77-0.91]; NAFLD FS, 0.74 [95% CI, 0.63-0.83]; FIB-4, 0.81 [95% CI, 0.72-0.89]; APRI, 0.73 [95% CI, 0.61-0.82]). Addition of VPI to any of the four scoring systems significantly improved the diagnostic value of the score for high-risk NAFLD. CONCLUSION. VPI may be an accurate noninvasive biomarker for diagnosis of high-risk NAFLD.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Baikpour M, Ozturk A, Dhyani M, et al. Portal Venous Pulsatility Index: A Novel Biomarker for Diagnosis of High-Risk Nonalcoholic Fatty Liver Disease. AJR Am J Roentgenol. 2020. PMID: 31939698. doi:10.2214/AJR.19.21963

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。